

RECEIVED
REGION 1

2006 FEB 21 PM 1:37

David Rhoe
CRMI
Paseo de la Fuente
D-4 Calle Tivoli
San Juan, PR 00926

February 11, 2006

Regional Administrator
U.S. Nuclear Regulatory Commission
Region I
475 Allendale Road
King of Prussia, PA 19406

J-9

03036911

RE: In house I-131 therapies (52-25430-03)

Dear Sir or Madam:

During the change of ownership from Mennonite General Hospital license (52-25058-01) to CRMI. The authorization to perform in-house I-131 therapies was not clarified based on our recent NRC inspection. Therefore the attached agreement has been enclosed to allow for in-house I-131 therapies at the Mennonite Hospital. Please review our NRC license and if needed amend it to allow for I-131 therapy.

If you need further information, please feel free to contact me at (787) 245-7248.

Sincerely,



David Rhoe.

138464
NRC/REGIONAL MATERIALS-002

Agreement Between Mennonite Hospital and CRMI
Performing Hospitalized I-131 Therapies

Definitions:

Control: Control of a room or area (within the hospital) is in the control of CRMI or persons who are empowered to decide when and how restricted access will be used. This also provides the authority to CRMI to authorize hospital personnel to control and supervise controlled areas. The Director of the Mennonite Hospital authorizes this delegated control explicitly.

Access: Access to a room(s) or another area(s) (within the hospital) is authorized to CRMI or persons who are empowered by CRMI to perform their duties as required by the Nuclear Regulatory Commission or other regulatory agencies. The Director of the Mennonite Hospital authorizes this delegated access explicitly.

Requirements for I-131 Therapies


1. Room where inpatient therapies will take place: 202
2. During any therapy, the room listed under item 1 will be under the direct control of CRMI or a designated person.
3. During any therapy, hospital personnel under the direct control of CRMI or a designated person will oversee visitor control.
4. CRMI or a designated person will train hospital staff regarding radiation safety, access and visitor control of an I-131 therapy room.
5. Before the room is released, CRMI or a designated person will perform a radiation contamination survey. The Hospital staff will restrict the access to these room(s) or area(s) until it is released.
6. CRMI or a designated person will perform the necessary surveys as required by the Nuclear Regulatory Commission or other Regulatory agencies.
7. Mennonite Hospital will allow CRMI or a designated person access to the hospital to perform their duties as required by the Nuclear Regulatory Commission or other regulatory agencies.
8. All radioactive waste from the I-131 therapies will be transferred by CRMI or a designated person to the Nuclear Medicine department and will be disposed according to Nuclear Regulatory Commission regulations.

9. CRMI or a designated person will provide the necessary equipment to perform the radiation surveys required by the Nuclear Regulatory Commission or other regulatory agencies.
10. Hospital personnel may contact CRMI or a designated person, or the Nuclear Regulatory Commission and/or other regulatory agencies if they have any question or concern regarding radiation safety at the Mennonite Hospital.
11. Records regarding radiation survey will be maintained by CRMI according to the Nuclear Regulatory Commission and/or other regulatory agencies.
12. Facility's address where access will be allowed:

Mennonite General Hospital
Calle José Vazquez Esq. Dr. Troyer
Aibonito, PR 00705-1379
(787) 735-8001 Ext. 1403
(787) 735-8082 Ext. 1558

13. Both parties will abide by all constraints, conditions, requirements and commitments as required by the Nuclear Regulatory Commission and/or other Regulatory agencies.

Mennonite General Hospital


Miguel Bustelo, MHSA


Sandra Gracia-López, MD

February 1, 2006

This is to acknowledge the receipt of your letter/application dated

2/11/2006, and to inform you that the initial processing which includes an administrative review has been performed.

AMCNS, 52-25430-03 There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 138464.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.